TrialSignal
Clinical trial intelligence report
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03479762-Jul 28, 2026
NCT ID
NCT03479762
Status
COMPLETED
Phase
registry-stage
Sponsor
Novo Nordisk A/S
Executive brief
Investment-Ready Snapshot
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity, Overweight. SEO and diligence focus: Liraglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03479762
Indication
Obesity
Modality
small molecule
Target
Liraglutide
Intervention
Liraglutide
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.